No data to show
XNAS
KNSA
Market cap1.59bUSD
Apr 02, Last price
21.85USD
1D
0.37%
1Q
9.58%
IPO
12.57%
Name
Kiniksa Pharmaceuticals Ltd
Chart & Performance
P/E
—
P/S
3.75
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.73%
Rev. gr., 5y
%
Revenues
423m
+56.60%
Net income
-43m
L
CFO
26m
+93.14%
Earnings
Jun 05, 2025
Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 423,239 56.60% | 270,259 22.74% | 220,180 471.24% | ||||||
Cost of revenue | 111,623 | 132,621 | 112,456 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 311,616 | 137,638 | 107,724 | ||||||
NOPBT Margin | 73.63% | 50.93% | 48.93% | ||||||
Operating Taxes | 7,041 | (30,736) | (172,337) | ||||||
Tax Rate | 2.26% | ||||||||
NOPAT | 304,575 | 168,374 | 280,061 | ||||||
Net income | (43,193) -406.68% | 14,084 -92.32% | 183,363 -216.11% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (4,984) | (2,206) | 2,516 | ||||||
BB yield | 0.35% | 0.17% | -0.24% | ||||||
| Debt | |||||||||
Debt current | 3,986 | 4,506 | 3,301 | ||||||
Long-term debt | 17,717 | 22,263 | 8,537 | ||||||
Deferred revenue | 11,954 | 12,000 | |||||||
Other long-term liabilities | 33,634 | 1,858 | 1,839 | ||||||
Net debt | (221,924) | (179,602) | (178,770) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 25,689 | 13,301 | 5,807 | ||||||
CAPEX | (277) | (130) | (105) | ||||||
Cash from investing activities | 37,672 | (29,557) | (8,078) | ||||||
Cash from financing activities | 12,266 | 1,495 | 2,516 | ||||||
FCF | 316,968 | 160,673 | 272,715 | ||||||
| Balance | |||||||||
Cash | 243,627 | 206,371 | 190,608 | ||||||
Long term investments | |||||||||
Excess cash | 222,465 | 192,858 | 179,599 | ||||||
Stockholders' equity | (521,286) | (477,924) | (491,971) | ||||||
Invested Capital | 1,005,204 | 945,086 | 19,695 | ||||||
ROIC | 31.23% | 34.90% | 2,149.11% | ||||||
ROCE | 64.39% | 29.46% | 25.90% | ||||||
| EV | |||||||||
Common stock shares outstanding | 71,424 | 71,923 | 70,421 | ||||||
Price | 19.78 12.77% | 17.54 17.09% | 14.98 27.27% | ||||||
Market cap | 1,412,770 11.99% | 1,261,528 19.59% | 1,054,911 30.70% | ||||||
EV | 1,190,846 | 1,081,926 | 876,141 | ||||||
EBITDA | 313,311 | 139,979 | 110,126 | ||||||
EV/EBITDA | 3.80 | 7.73 | 7.96 | ||||||
Interest | 1,253 | ||||||||
Interest/NOPBT | 1.16% | ||||||||